Agents/regimens | No. of patients | No. of events, n (%) | HR | 95 % CI | P value | |
---|---|---|---|---|---|---|
Eribulin monotherapy | 66 | 39 (59.1) | 0.55 | 0.36–0.85 | 0.01* | |
Anthracycline-based regimen | 136 | 120 (88.2) | 1.35 | 1.01–1.82 | 0.04* | |
Paclitaxel monotherapy | 138 | 103 (74.6) | 1.14 | 0.85–1.52 | 0.38 | |
Docetaxel monotherapy | 79 | 72 (91.1) | 1.30 | 0.95–1.79 | 0.10 | |
Capecitabine monotherapy | 120 | 100 (83.3) | 0.89 | 0.66–1.20 | 0.43 | |
Gemcitabine monotherapy | 12 | 12 (83.3) | 0.55 | 0.27–1.10 | 0.09 | |
Vinorelbine monotherapy | 37 | 37 (100.0) | 1.15 | 0.76–1.73 | 0.51 | |
Paclitaxel + bevacizumab | 52 | 52 (57.7) | 1.51 | 0.93–2.48 | 0.10 | |
Docetaxel + capecitabine | 30 | 30 (96.7) | 1.13 | 0.74–1.73 | 0.57 | |
Paclitaxel + gemcitabine | 10 | 10 (100.0) | 2.79 | 1.34–5.79 | 0.01* |